Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
Venture Capital News Daily
RubrYc Therapeutics Inks $10M Series A Round

       
SAN RAMON, CA, Biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventures.
Click here for more funding data on RubrYc Therapeutics
To export RubrYc Therapeutics funding data to PDF and Excel, click here
RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it has closed a $10 million Series A Preferred Equity financing round led by Third Point Ventures, with participation by Paladin Capital Group and Vital Venture Capital.

"Our development of unique chemical libraries has allowed us to map the surfaces of drug targets with unprecedented resolution, and to identify off target binding events that hamper drug discovery and development," said Dr. Isaac Bright, CEO of RubrYc Therapeutics. "With our Series A financing, which completes our spin-off from HealthTell, Inc., we are continuing to build our antibody discovery platform, proprietary pipeline of therapeutic candidates, and actively initiating new pharmaceutical partnerships."

RubrYc is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company will be collaborating with biotechnology companies in early drug discovery and developing its own molecules.

"I am excited to launch RubrYc Therapeutics and believe that the company's applications of our technology address important challenges in antibody characterization. We are already seeing results in the earliest phases of RubrYc programs, and I look forward to supporting the team as the company grows," said Bill Colston, CEO of HealthTell and Executive Chairman of RubrYc Therapeutics.

About RubrYc Therapeutics

Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc. The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development.
(c)2011-2018 by Massinvestor, Inc. For contact info, please check out our about page.
  >> Click here for in-depth research on 4,000 VC firms
Venture Capital News Daily
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.